LivaNova stock gains as Piper Sandler raises price target on strong Q2 results

LivaNova PLC stock (ISIN US5356991077) is trading close to its 52-week high after the medical-technology company reported strong second-quarter 2026 figures and attracted a fresh price-target increase from Piper Sandler, according to market data as of September 2, 2026.

Analyst upgrade supports LivaNova stock

According to a report on Investing.com dated September 2, 2026, Piper Sandler has raised its price target for LivaNova stock to USD 90 from USD 87 while maintaining an Overweight rating, reflecting increased confidence in the company’s cardiopulmonary growth outlook.

The same analysis notes that LivaNova shares recently traded at about USD 82.69, implying close to 9% potential upside to the new Piper Sandler target if the stock were to reach USD 90.

A separate overview on Investing.com South Africa highlights that the shares are trading near a 52-week high of USD 85.76, with a year-to-date gain of about 30%, underlining how strongly the market has rewarded the company’s recent execution.

Q2 2026 results and guidance raise

LivaNova’s latest fundamental driver is its second-quarter 2026 performance. As summarized by the Investing.com analyst report, the company achieved adjusted earnings of USD 1.26 per share in Q2 2026, comfortably above Wall Street expectations of USD 1.09 per share, meaning earnings came in USD 0.17 per share ahead of consensus.

In the same quarter, LivaNova generated revenue of USD 390.6 million, which also exceeded analyst forecasts cited in the Investing.com coverage, positioning the company’s top line above expectations for Q2 2026.

Following these stronger-than-anticipated results, LivaNova raised its full-year 2026 guidance for both organic revenue growth and earnings per share, according to the same Investing.com report, signaling management’s improved confidence in the outlook for the remainder of the year.

A further perspective from GuruFocus calculates a proprietary GF Value of USD 63.49 for LivaNova shares compared with a recent market price of USD 82.85, implying that, on this specific valuation model, the stock is about 30.5% above its estimated fair value.

Insider transactions add another data point

Recent SEC filings provide additional color on insider activity at LivaNova. A Form 4 filing summarized by Stock Titan shows that director Francesco Bianchi sold 1,650 ordinary shares of LivaNova PLC on August 31, 2026 at a price of USD 79.72 per share, for a total transaction value of about USD 131,538.

Another filing summarized on Stock Titan describes a planned Rule 144 sale by officer Franco Poletti covering 10,755 LivaNova shares with an aggregate market value of USD 882,888.36, with the notice indicating potential sales on or after September 2, 2026 on NASDAQ through Merrill Lynch.

In addition, a separate Form 3 filing outlined by Stock Titan notes that Anne M. Liddy, LivaNova’s chief legal officer, has become a reporting insider, although that document lists no specific equity holdings or transactions at the time of filing.

Representative product and cardiopulmonary focus

LivaNova is best known for its cardiopulmonary and neuromodulation portfolios, supplying devices and systems used in cardiac surgery and cardiovascular support worldwide. A central example is its advanced heart-lung machine platforms, which provide life support during open-heart procedures and represent a key revenue driver in its cardiopulmonary segment.

The Piper Sandler commentary on Investing.com explicitly cites cardiopulmonary growth prospects as a reason for the higher price target, indicating that demand for LivaNova’s capital equipment and disposables in this area is a significant part of the firm’s medium-term growth narrative.

Stock price level and trading data

Market data compiled by Yahoo Finance show that LivaNova stock recently traded around USD 79.81, with an intraday range between USD 78.49 and USD 80.62 as of the latest available trading session prior to September 3, 2026.

The same Yahoo Finance overview lists a 52-week range from USD 48.82 to USD 85.76 for LivaNova shares, placing the current price clearly closer to the upper end of that band and illustrating how strongly the stock has appreciated over the past year.

According to the Investing.com South Africa summary, LivaNova’s share price has risen by about 30.28% year to date, underscoring that the combination of better-than-expected Q2 2026 figures and raised guidance has been rewarded with a substantial re-rating by the equity market.

Key data for LivaNova stock

• Company: LivaNova PLC
• ISIN: US5356991077
• Ticker: LIVN
• Trading venue: NASDAQ
• Price (as of September 2, 2026): 79.81 USD
• Sector / Industry: Health care equipment
• Index membership: S&P 500